Related Experiment Video

Updated: Feb 24, 2026

Live Imaging to Study Microtubule Dynamic Instability in Taxane-resistant Breast Cancers
06:02

Live Imaging to Study Microtubule Dynamic Instability in Taxane-resistant Breast Cancers

Published on: February 20, 2017

8.0K

Fighting tubulin-targeting anticancer drug toxicity and resistance

Roberta Visconti1, Domenico Grieco2,3

  • 1Institute for the Experimental Endocrinology and Oncology 'G. Salvatore'Italian National Council of Research, Napoli, Italy r.visconti@ieos.cnr.it domenico.grieco@unina.it.

Endocrine-Related Cancer
|August 16, 2017
PubMed

Insights

Anti-microtubule cancer drugs (AMCDs) show promise for treating aggressive cancers but cause side effects and resistance. Co-targeting WEE1 and MYT1 kinases may enhance AMCD effectiveness and reduce toxicity.

Area of Science:

  • Oncology
  • Pharmacology
  • Cell Biology

Background:

  • Anti-microtubule cancer drugs (AMCDs), including taxanes and vinca alkaloids, are vital in treating castration-resistant prostate cancer and triple-negative breast cancer.
  • AMCDs are limited by toxicities like neutropenia and neurotoxicity, and the development of tumor resistance.
  • Tumor resistance and drug-related toxicities necessitate novel therapeutic strategies.

Purpose of the Study:

  • To explore strategies for improving the efficacy of AMCDs in treating resistant cancers.
  • To investigate the potential of co-targeting mitotic progression with WEE1 and MYT1 kinase inhibition.
  • To discuss alternative treatments, including new AMCD formulations and different molecular targets.

Main Methods:

  • Review of current literature on AMCDs, WEE1 and MYT1 kinases, and cancer resistance mechanisms.
  • Analysis of preclinical and clinical data regarding combination therapies.
  • Discussion of emerging therapeutic approaches for castration-resistant prostate cancer and triple-negative breast cancer.

Main Results:

  • Co-targeting mitotic progression regulators (WEE1, MYT1) alongside AMCDs may overcome resistance and reduce toxicity.
  • Targeting WEE1 and MYT1 influences CDK1 kinase activity, impacting cell division.
  • New AMCD formulations and alternative molecular targets represent promising avenues for improving patient outcomes.

Conclusions:

  • Co-targeting WEE1 and MYT1 offers a potential strategy to enhance AMCD efficacy and mitigate adverse effects.
  • Further research into combination therapies and novel molecular targets is crucial for advancing treatment for resistant cancers.
  • Optimizing AMCD therapy through formulation or target selection can improve clinical outcomes for challenging malignancies.
Keywords:
MYT1WEE1 inhibitorcastration-resistant prostate cancermitosisspindle assembly checkpointtaxanetriple-negative breast cancervinca alkaloids

More Related Videos

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel06:44

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel

Published on: September 8, 2017

14.1K
Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo09:19

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

Published on: February 6, 2015

9.2K

Related Concept Videos

Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.8K
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
4.1K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.2K
Destabilization of Microtubules01:45

Destabilization of Microtubules

The destabilization of microtubules can occur during different stages of the microtubule lifecycle, such as nucleation or elongation. It can take place at either end of the microtubule or in the microtubule lattices as a whole. The lifespan of individual microtubules within a cell varies according to the cell type and stage of the cell cycle. During interphase, the lifespan of the microtubule is about 30 minutes, while during cell division, it is about 15 minutes. In axonal microtubules of...
3.7K